Centers for Disease Control and Prevention, Division of Bacterial Diseases, Respiratory Diseases Branch, Atlanta, Georgia, United States of America.
PATH, Seattle, Washington, United States of America.
PLoS One. 2019 Apr 18;14(4):e0215753. doi: 10.1371/journal.pone.0215753. eCollection 2019.
Infectious disease nucleic acid amplification technologies (NAAT) have superior sensitivity, specificity, and rapid time to result compared to traditional microbiological methods. Recovery of concentrated, high quality pathogen nucleic acid (NA) from complex specimen matrices is required for optimal performance of several NA amplification/detection technologies such as polymerase chain reaction (PCR). Fully integrated NAAT platforms that enable rapid sample-to-result workflows with minimal user input are generally restricted to larger reference lab settings, and their complexity and cost are prohibitive to widespread implementation in resource limited settings (RLS). Identification of component technologies for incorporation of reliable and affordable sample preparation with pathogen NA amplification/detection into an integrated platform suitable for RLS, is a necessary first step toward achieving the overarching goal of reducing infectious disease-associated morbidity and mortality globally. In the current study, we evaluate the performance of six novel NA extraction technologies from different developers using blinded panels of stool, sputum and blood spiked with variable amounts of quality-controlled DNA- and/or RNA-based microbes. The extraction efficiencies were semi-quantitatively assessed using validated real-time reverse transcription (RT)-PCR assays specific for each microbe and comparing target-specific RT-PCR results to those obtained with reference NA extraction methods. The technologies were ranked based on overall diagnostic accuracy (analytical sensitivity and specificity). Sample input and output volumes, total processing time, user-required manual steps and cost estimates were also examined for suitability in RLS. Together with the performance analysis, these metrics were used to select the more suitable candidate technologies for further optimization of integrated NA amplification and detection technologies for RLS.
传染病核酸扩增技术 (NAAT) 与传统微生物方法相比,具有更高的灵敏度、特异性和快速的结果时间。为了优化几种 NA 扩增/检测技术(如聚合酶链反应(PCR))的性能,需要从复杂的标本基质中回收浓缩的、高质量的病原体核酸(NA)。能够实现快速样本到结果工作流程、用户输入最少的完全集成的 NAAT 平台通常仅限于更大的参考实验室环境,其复杂性和成本使其在资源有限的环境(RLS)中广泛实施变得困难。确定将可靠且负担得起的样本制备与病原体 NA 扩增/检测相结合的组件技术,并将其整合到适合 RLS 的平台中,是实现减少全球传染病相关发病率和死亡率这一总体目标的必要第一步。在当前的研究中,我们使用不同开发商的六种新型 NA 提取技术对盲样进行评估,这些盲样分别为含有不同数量经质量控制的 DNA 和/或 RNA 微生物的粪便、痰液和血液。使用针对每种微生物的经过验证的实时逆转录(RT)-PCR 检测,对提取效率进行半定量评估,并将针对特定目标的 RT-PCR 结果与参考 NA 提取方法的结果进行比较。根据总体诊断准确性(分析灵敏度和特异性)对技术进行排名。还检查了样本输入和输出量、总处理时间、用户所需的手动步骤和成本估算,以评估其在 RLS 中的适用性。除了性能分析,这些指标还用于选择更合适的候选技术,以进一步优化适合 RLS 的集成 NA 扩增和检测技术。